CSIMarket Company Name, Ticker, Industry, else..
 
Hepion Pharmaceuticals Inc   (HEPA)
 
Price: $0.0900 $0.00 -5.263%
Day's High: $0.09000000357627869 Week Perf: 21.62 %
Day's Low: $ 0.08 30 Day Perf: 95.65 %
Volume (M): 633 52 Wk High: $ 0.11
Volume (M$): $ 0 52 Wk Avg: $0.06
Open: $0.09 52 Wk Low: $0.03



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 12
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Hepion Pharmaceuticals Inc. is a biopharmaceutical company that is focused on the development of innovative therapies for liver diseases. The company's primary area of expertise is in the research and development of drugs targeting fibrosis, a common complication of chronic liver disease. Hepion Pharmaceuticals aims to address the unmet medical needs of patients suffering from liver-related conditions by discovering and advancing novel therapeutic candidates. Their research efforts are primarily centered on developing drugs that can reduce fibrosis and improve liver function. The company is committed to bringing new treatment options to patients and improving their quality of life.


   Company Address: 34 Shrewsbury Ave., Red Bank 7701 NJ
   Company Phone Number: 902-4000   Stock Exchange / Ticker: HEPA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABUS   -2.31%    
ASMB   -4.68%    
CUE        10.09% 
CYCN   -6.36%    
REGN   -3.55%    
VRTX   -0.56%    
• View Complete Report
   



Product Service News

Hepion Pharmaceuticals to Unveil Groundbreaking Efficacy Data for Rencofilstat at AASLD 2023, Revolutionizing NASH Treatment

Published Fri, Nov 10 2023 1:50 PM UTC



Hepion Pharmaceuticals, a leading biopharmaceutical company focused on the development of innovative therapeutics for liver diseases, has recently announced the scheduling of a conference call to review additional efficacy data from its Phase 2 ALTITUDE-NASH liver function trial of Rencofilstat. The highly anticipated data release is set to follow a late-breaker po...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.56
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.54
Working Capital Ratio 3.68
Leverage Ratio (MRQ) 0.46
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.27 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.22 $
Book Value 0.16 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.